Therefore, further studies will be required using larger patient groups with germline mutations, in particular those with a truncating mutation in the CHEK2 gene, to assess whether patients with increased expression of CHK2 and p53 in cancer cells, especially their phosphorylated forms, require different treatment regimens or oncological follow-up protocols from those of patients with tumors that do not express these genes. The gene discussed is TP53; the disease is cancer.